Compare · BDX vs TMO
BDX vs TMO
Side-by-side comparison of Becton Dickinson and Company (BDX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BDX operates in Health Care, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $214.46B, about 4.4x BDX ($48.79B).
- Over the past year, BDX is down 6.0% and TMO is up 28.5% - TMO leads by 34.4 points.
- BDX has been more active in the news (11 items in the past 4 weeks vs 4 for TMO).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Thermo Fisher Scientific Inc
- Price
- $176.47-0.32%
- $584.23+0.73%
- Market cap
- $48.79B
- $214.46B
- 1M return
- +16.98%
- +11.37%
- 1Y return
- -5.96%
- +28.46%
- Industry
- Medical/Dental Instruments
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BDX
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
- EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,785 worth of shares (75 units at $157.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 20,934 units (SEC Form 4)
- UBS initiated coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest TMO
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports Second Quarter 2026 Results
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S